


## Isavuconazole

## Chemical Properties

CAS No. :	241479-67-4
Formula:	C <sub>22</sub> H <sub>17</sub> F <sub>2</sub> N <sub>5</sub> O <sub>5</sub>
Molecular Weight:	437.47
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Isavuconazole (RO-0094815)(BAL-4815; RO-0094815) is the active component of the new azole antifungal agent BAL8557 with MIC(50)s/MIC(90)s ranged from 0.002/0.004 mg/liter for <i>C. albicans</i> to 0.25/0.5 mg/liter for <i>C. glabrata</i> .
Targets(IC50)	Antibiotic,Antifungal,Cytochromes P450
Kinase Assay	SP2509 activity assays: Test compounds are diluted to 20 × the desired test concentration in 100% DMSO and 2.5 μL of the diluted drug sample is added to a black 384-well plate. The LSD1 enzyme stock is diluted 17-fold with assay buffer and 40 μL of the diluted LSD1 enzyme is added to the appropriate wells. Substrate, consisting of horseradish peroxidase, dimethyl K4 peptide corresponding to the first 21 amino acids of the N-terminal tail of histone H3, and 10-acetyl-3,7-dihydroxyphenoxazine is then added to wells. Resorufin is analyzed on an Envision plate reader with an excitation wavelength of 530 nm and an emission wavelength of 595 nm. The activity of SP2509 on the other oxidases is determined by using commercially available kits. The glucose oxidase activity (which also noncovalently binds FAD in an elongate conformation), is determined using the glucose oxidase kit. The MAO assays are performed using the MAO-glo kit with MAO-A and MAO-B.

## Solubility Information

Solubility	DMSO: 250 mg/mL (571.47 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.57 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2859 mL	11.4294 mL	22.8587 mL
5 mM	0.4572 mL	2.2859 mL	4.5717 mL
10 mM	0.2286 mL	1.1429 mL	2.2859 mL
50 mM	0.0457 mL	0.2286 mL	0.4572 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

## Reference

Seifert H, et al. *Antimicrob Agents ChemOthers*. 2007 May;51(5):1818-21.

Ma L, Lian Y, Tang J, et al. Identification of the Anti-Fungal Drug Fenticonazole Nitrate as a Novel PPAR $\gamma$ -Modulating Ligand With Good Therapeutic Index: Structure-Based Screening and Biological Validation. *Pharmacological Research*. 2021: 105860.

Lau S K P, Xing F, Tsang C C, et al. Clinical characteristics, rapid identification, molecular epidemiology and antifungal susceptibilities of *Talaromyces marneffe* infections in Shenzhen, China[J]. *Mycoses*. 2019 May;62(5): 450-457.

Quan C, Chen Y, Wang X, et al. Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer. *Cancer Letters*. 2020

Tsang C C, Tang J Y M, Chan K F, et al. Diversity of phenotypically non-dermatophyte, non-*Aspergillus* filamentous fungi causing nail infections: importance of accurate identification and antifungal susceptibility testing. *Emerging Microbes & Infections*. 2019, 8(1): 531-541

Tsang C C, Tang J Y M, Ye H, et al. Rare/cryptic *Aspergillus* species infections and importance of antifungal susceptibility testing[J]. *Mycoses*. 2020, 63(12): 1283-1298.

Tsang C C, Chan K F, Chan W, et al. Hepatic phaeohyphomycosis due to a novel dematiaceous fungus, *Pleurostoma hongkongense* sp. nov., and importance of antifungal susceptibility testing[J]. *Emerging Microbes & Infections*. 2020: 1-53.

Tsang C C, Chan K F, Chan W, et al. Hepatic phaeohyphomycosis due to a novel dematiaceous fungus, *Pleurostoma hongkongense* sp. nov., and importance of antifungal susceptibility testing. *Emerging Microbes & Infections*. 2021 Dec;10(1):81-96.

Tsang C C, Tang J Y M, Chan K F, et al. Diversity of phenotypically non-dermatophyte, non-*Aspergillus* filamentous fungi causing nail infections: importance of accurate identification and antifungal susceptibility testing[J]. *Emerging microbes & infections*. 2019;8(1):531-541.

Lau S K P, Xing F, Tsang C C, et al. Clinical characteristics, rapid identification, molecular epidemiology and antifungal susceptibilities of *Talaromyces marneffe* infections in Shenzhen, China. *Mycoses*. 2019, 62(5): 450-457

Wu X, Wang Z, Liang Z, et al. Pleiotropic role of CCR9/CCL25 signaling in adriamycin-induced cardiomyopathy. *Journal of Advanced Research*. 2024

Diversity and Antifungal Susceptibilities of Yeasts from Mangroves in Hong Kong, China-A One Health Aspect

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481